BIO$256.56
$257
Chart
Performance
Key Stats
AI BIO Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyBio-Rad Laboratories demonstrates a mixed investment profile. Fundamentally, it shows strong profitability and manageable debt, supported by positive growth trends. However, its current valuation appears stretched, and technical indicators suggest some short-term consolidation or caution is warranted. The thematic outlook is neutral to positive.
Thematic
Bio-Rad operates in the life science and clinical diagnostics sectors, benefiting from ongoing demand for research and healthcare solutions. However, it does not appear to be at the forefront of disruptive technological themes like AI or renewable energy, leading to a more neutral thematic score.
Fundamental
Bio-Rad demonstrates strong financial health with robust profitability and a solid balance sheet. Revenue and EPS trends show some volatility but overall positive surprises in recent quarters. Valuation metrics like P/E are high, suggesting growth is priced in.
Technical
The stock has shown strong recent performance (5D, 1M) but weaker longer-term trends (6M, 1Y). Technical indicators suggest a bullish trend is forming, with moving averages generally indicating 'Buy', but some oscillators are in neutral or approaching overbought territory.
| Factor | Score |
|---|---|
| Life Science Research Demand | 70 |
| Clinical Diagnostics Market | 65 |
| Biopharmaceutical Manufacturing Support | 60 |
| Digital Health Integration | 40 |
| ESG & Sustainability | 50 |
| Factor | Score |
|---|---|
| Valuation | 20 |
| Profitability | 80 |
| Growth | 40 |
| Balance Sheet Health | 85 |
| Cash Flow | 85 |
| Earnings Surprise | 85 |
| Factor | Score |
|---|---|
| Trend Analysis | 70 |
| Momentum | 60 |
| Volume Confirmation | 50 |
| Short-Term Performance | 75 |
| Support & Resistance | 60 |
AI Investing Checklist
Powered by LiveAIBullish Points (8)
Positive EPS Surprises
The company has exceeded earnings per share (EPS) estimates in multiple recent quarters (e.g., Q2 2024, Q4 2024), indicating robust operational performance and effective cost management.
Attractive Price-to-Sales Ratio (PS)
The current Price-to-Sales (PS) ratio of 3.7 (TTM) is relatively low compared to historical averages and industry peers, suggesting potential undervaluation or a buying opportunity.
Bearish Points (8)
Very High Price-to-Earnings Ratio (P/E)
The TTM P/E ratio is exceptionally high at 5189.4, indicating the stock is trading at a significant premium and may be overvalued, especially given recent negative net income.
Significant Net Loss in 2024
The company reported a substantial net loss of -$1.84 billion in 2024, with a negative net margin of -71.9%, signaling significant profitability challenges.
Calendar
August 2025
1
Next Earnings Date
H: $1.92
A: $1.75
L: $1.60
H: 617.30M
A: 614.29M
L: 608.80M
Profile
Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials, such as cells, proteins, and nucleic acids used in biopharmaceutical manufacturing, quality control process, food safety, and science education applications. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, and transfusion and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Seasonals
Price Target
315.33 USD
The 39 analysts offering 1 year price forecasts for BIO have a max estimate of 387.00 and a min estimate of 245.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 98
Diversified healthcare giant with a significant pharmaceutical division heavily involved in biotech R&D, drug discovery, and vaccine development.
Weight: 97
Major pharmaceutical company with a robust pipeline in diabetes, obesity, neuroscience, and oncology, largely driven by biotechnology research and development.
Weight: 96
Global pharmaceutical leader with extensive biotechnology R&D, particularly strong in oncology (e.g., Keytruda) and vaccine development.
Weight: 95
Major pharmaceutical company with significant investments and acquisitions in biotechnology, leading in vaccines, oncology, and rare disease therapies.